Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL M DAO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1437321932
CMS profile
337948
Location
GARDEN GROVE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$10,507.47

306 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $7,414.97 303
Consulting Fee $3,050.00 2
Education $42.50 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Agios Pharmaceuticals, Inc. $3,106.74 4
Amgen Inc. $896.74 47
AstraZeneca Pharmaceuticals LP $724.36 13
ABBVIE INC. $639.87 25
Aimmune Therapeutics, Inc. $428.58 23
Ardelyx, Inc. $390.64 19
Axsome Therapeutics, Inc. $370.04 7
Phathom Pharmaceuticals, Inc. $315.35 10
Novartis Pharmaceuticals Corporation $280.39 21
Viatris Specialty LLC $266.04 7
GlaxoSmithKline, LLC. $226.74 13
Neurocrine BioSciences, Inc. $226.37 4
Bayer Healthcare Pharmaceuticals Inc. $211.70 15
Gilead Sciences, Inc. $208.73 4
Kowa Pharmaceuticals America, Inc. $160.35 9
Lilly USA, LLC $146.79 6
MAYNE PHARMA COMMERCIAL LLC $121.37 1
Novo Nordisk Inc $116.97 6
Verona Pharma, Inc. $107.15 4
Salix Pharmaceuticals, a division of Bausch Health US, LLC $99.20 5
Sumitomo Pharma America, Inc. $90.68 4
Mannkind Corporation $88.23 3
Lundbeck LLC $79.30 3
TOLMAR, INC. $79.10 4
Biogen, Inc. $75.90 3
Corcept Therapeutics $73.29 3
Janssen Biotech, Inc. $71.02 3
Radius Health, Inc. $59.70 2
Otsuka America Pharmaceutical, Inc. $58.78 3
Dexcom, Inc. $55.64 3
CeQur Corporation $54.74 1
Madrigal Pharmaceuticals $49.91 2
VIVUS LLC $47.17 2
PFIZER INC. $45.98 2
Teva Pharmaceuticals USA, Inc. $45.81 2
Insulet Corporation $45.59 2
Boehringer Ingelheim Pharmaceuticals, Inc. $44.72 2
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $41.54 2
Abbott Laboratories $36.53 2
Optinose US, Inc. $36.34 2
Merck Sharp & Dohme LLC $35.86 2
Organon LLC $30.22 1
Regeneron Healthcare Solutions, Inc. $25.99 1
AERIN MEDICAL INC. $24.50 1
Averitas Pharma Inc. $23.97 1
Medtronic, Inc. $22.97 1
IRONWOOD PHARMACEUTICALS, INC $22.16 1
IBSA Pharma Inc. $21.76 1
Paratek Pharmaceuticals, Inc. $19.43 1
Integra LifeSciences Corporation $18.99 1
ANI Pharmaceuticals, Inc. $18.79 1
Verity Pharmaceuticals Inc. $18.74 1

Page 6 of 7; records 251–300 of 306 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL M DAO

NPI 1437321932 · CMS profile ID 337948

Allopathic & Osteopathic Physicians / Internal Medicine

GARDEN GROVE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 7; records 251–300 of 306 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1437321932?year=2025&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL M DAO, NPI 1437321932, CMS profile ID 337948. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 7; records 251–300 of 306 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437321932?year=2025&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MICHAEL M DAO, NPI 1437321932, CMS profile ID 337948. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 7; records 251–300 of 306 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437321932?year=2025&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MICHAEL M DAO, NPI 1437321932, CMS profile ID 337948, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 7; records 251–300 of 306 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1437321932?year=2025&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

306 matching records · $10,507.47 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 306 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–300 of 306.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $27.4203/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186818480 CMS
Janssen Biotech, Inc. $24.0103/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174622337 CMS
ANI Pharmaceuticals, Inc. $18.7903/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248652809 CMS
Aimmune Therapeutics, Inc. $23.9003/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249694459 CMS
Ardelyx, Inc. $28.5203/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247843417 CMS
ABBVIE INC. $15.5203/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201725998 CMS
AERIN MEDICAL INC. $24.5003/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249132214 CMS
Axsome Therapeutics, Inc. $24.6003/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235518844 CMS
Biogen, Inc. $24.2403/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208318900 CMS
Lilly USA, LLC $22.6703/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186755807 CMS
PFIZER INC. $22.6703/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231384306 CMS
ABBVIE INC. $123.8602/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201725996 CMS
Amgen Inc. $8.5902/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227136663 CMS
Kowa Pharmaceuticals America, Inc. $21.0902/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243083243 CMS
Otsuka America Pharmaceutical, Inc. $26.2102/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227315813 CMS
Corcept Therapeutics $23.9702/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214240722 CMS
GlaxoSmithKline, LLC. $26.0702/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191385688 CMS
Phathom Pharmaceuticals, Inc. $23.6502/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219337990 CMS
Novartis Pharmaceuticals Corporation $4.6202/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200142431 CMS
Novartis Pharmaceuticals Corporation $15.6102/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200142433 CMS
Viatris Specialty LLC $21.0302/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238495109 CMS
Aimmune Therapeutics, Inc. $10.8802/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249694429 CMS
Axsome Therapeutics, Inc. $21.1202/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235394983 CMS
Ardelyx, Inc. $25.5602/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247843415 CMS
Dexcom, Inc. $19.9002/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250508862 CMS
Neurocrine BioSciences, Inc. $136.1202/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242963569 CMS
AstraZeneca Pharmaceuticals LP $19.5702/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207166561 CMS
Bayer Healthcare Pharmaceuticals Inc. $12.5802/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225510058 CMS
Novo Nordisk Inc $23.7202/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188823521 CMS
Aimmune Therapeutics, Inc. $11.7402/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249694435 CMS
Gilead Sciences, Inc. $26.0002/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234466069 CMS
ABBVIE INC. $12.1402/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201725994 CMS
Amgen Inc. $23.6402/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228300278 CMS
Gilead Sciences, Inc. $120.2502/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234390632 CMS
VIVUS LLC $21.7802/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188051041 CMS
ABBVIE INC. $5.6901/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201725992 CMS
Aimmune Therapeutics, Inc. $10.9301/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249694433 CMS
ABBVIE INC. $24.2401/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201725990 CMS
Aimmune Therapeutics, Inc. $27.3301/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249694467 CMS
Amgen Inc. $10.0001/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227136661 CMS
Amgen Inc. $13.0001/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227136675 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.4401/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223033768 CMS
Bayer Healthcare Pharmaceuticals Inc. $15.9901/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225510056 CMS
Novartis Pharmaceuticals Corporation $15.5701/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200142429 CMS
Ardelyx, Inc. $24.1701/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247843413 CMS
TOLMAR, INC. $21.1501/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237001623 CMS
Phathom Pharmaceuticals, Inc. $10.4101/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219338070 CMS
Viatris Specialty LLC $26.1501/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238464005 CMS
ABBVIE INC. $18.1701/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201725988 CMS
IRONWOOD PHARMACEUTICALS, INC $22.1601/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227660523 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,431.84 316
PY2020 $7,527.22 245
PY2021 $6,862.27 337
PY2022 $6,263.60 258
PY2023 $6,441.40 281
PY2024 $7,580.36 302
PY2025 $10,507.47 306

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $550,613.82 26
PY2024 Principal investigator $344,392.32 269
PY2023 Principal investigator $842,190.10 383
PY2022 Principal investigator $391,336.90 273
PY2021 Principal investigator $231,496.56 57
PY2020 Principal investigator $6,000.00 3
PY2019 Principal investigator $55,715.00 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,477.14 12/19/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520600
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,711.35 12/17/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520609
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 12/10/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520604
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,766.00 11/11/2025 Non-covered Recipient Entity
National Institute Of Clinical Research, Inc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225415310
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,250.00 10/31/2025 Non-covered Recipient Entity
NATIONAL INSTITUTE OF CLINICAL RESEARCH
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185543644
Principal investigator 1 Alnylam Pharmaceuticals Inc. $758.41 10/24/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520612
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,064.50 08/27/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520534
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,400.00 08/06/2025 Non-covered Recipient Entity
NATIONAL INSTITUTE OF CLINICAL RESEARCH
A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of AZD0780 on Low-Density Lipoprotein Cholesterol in Patients With Heterozygous Familial Hypercholesterolaemia No dispute reported 06/30/2026 1185543640
Principal investigator 1 AstraZeneca Pharmaceuticals LP $349,547.00 07/31/2025 Non-covered Recipient Entity
NATIONAL INSTITUTE OF CLINICAL RESEARCH
A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event No dispute reported 06/30/2026 1185543642
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,206.58 07/16/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520531
Principal investigator 1 Alnylam Pharmaceuticals Inc. $53,106.60 07/14/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215520538
Principal investigator 1 Alnylam Pharmaceuticals Inc. $211.00 07/14/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215520542
Principal investigator 2 E.R. Squibb & Sons, L.L.C. $5,689.72 06/25/2025 Non-covered Recipient Entity
National Institute Of Clinical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease No dispute reported 06/30/2026 1235995507
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,366.00 05/29/2025 Non-covered Recipient Entity
National Institute Of Clinical Research, Inc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225412690
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,481.26 04/18/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520527
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,850.00 04/16/2025 Non-covered Recipient Entity
NATIONAL INSTITUTE OF CLINICAL RESEARCH
A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non cirrhotic Non alcoholic Steatohepatitis with Fibrosis No dispute reported 06/30/2026 1185543648
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,387.00 04/01/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520522
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $10,000.00 03/18/2025 Non-covered Recipient Entity
National Institute Of Clinical Research, Inc
BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney No dispute reported 06/30/2026 1225405276
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 03/12/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520490
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,538.30 03/12/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520494
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 02/21/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520484
Principal investigator 1 Alnylam Pharmaceuticals Inc. $426.42 02/21/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520487
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 02/21/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520508
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,483.14 02/03/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520498
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,645.28 02/03/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520504
Principal investigator 1 AstraZeneca Pharmaceuticals LP $37,248.12 01/29/2025 Non-covered Recipient Entity
NATIONAL INSTITUTE OF CLINICAL RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185543646